Fig. 1From: Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapyAssessing different cell populations ex vivo in PBMCs from healthy donors and BC patients before and after chemotherapy. a Paired analysis of tumor size (area in cm2) of the patients before therapy and after three cycles of A/C chemotherapy (n = 17). b Working strategy for multi-parametric cell analysis using flow cytometry. Monocytes and lymphocytes were defined by contour plots using SSC-A vs. FSC-A. Myeloid and plasmacytoid dendritic cell (DCs) (cells HLA-DR+ Lin1/CD15- CD11c + or HLA-DR+ Lin1/CD15- CD123+ respectively) and myeloid-derived suppressor cells (MDSCs) (cells HLA-DR- Lin1/CD15- CD13+ CD33+ ± Arginase 1+), were analyzed within the monocytic cell region. Finally, the percentage of CD4+ and regulatory T cells CD4+ CD25+ CD127- FoxP3+ (Tregs) was estimated within the lymphoid cell region. c Percentage of different sub-populations ex vivo in PBMCs from healthy donors (white box n = 10) and BC patients before (gray box n = 12) and after chemotherapy (dashed box n = 12). Panels summarize the percentages of DCs populations (top panel), MDSCs (middle panel) and CD4+ and CD4+ Tregs: CD4+ CD25+ CD127- and CD4+ CD25+ CD127- FoxP3+ (middle and right panels at the bottom). Paired analysis by Wilcoxon test, *** p < 0.001. Box and whiskers graph with 10–90% of dataBack to article page